(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.